{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:32Z","timestamp":1776850472928,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Tolazoline hydrochloride is usually the first choice pulmonary\nvasodilator in persistent pulmonary hypertension of the neonate\n(PPHN). The analysis of 26 articles including 467 tolazoline-\ntreated infants has been hindered by many methodological\ndrawbacks. Tolazoline has always been administered to infants\nsuffering refractory hypoxemia, but, unfortunately, pulmonary\nhypertension has not usually been investigated. Moreover,\n80% of the tolazoline-treated neonates had an underlying\npulmonary parenchymal disease as a potential cause of\nsevere hypoxemia. Noteworthy is that similar comments apply\nto all studies dealing with the use of other pulmonary vasodilators\nin PPHN. Pulsed Doppler echocardiography (PDE)\nshould allow a qualitative and quantitative approach for\nPPHN and an analysis of both success and failure of vasodilator\ntherapeutics. In the meantime, the use of PDE requires\nmore intense investigation prior to wide application in\nPPHN.<\/jats:p>","DOI":"10.1159\/000457466","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:22Z","timestamp":1502471302000},"page":"62-68","source":"Crossref","is-referenced-by-count":6,"title":["Vasodilators in Persistent\nPulmonary Hypertension of the\nNewborn: A Need for Optimal\nAppraisal of Efficacy"],"prefix":"10.1159","author":[{"given":"J.B.","family":"Gouyon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fran\u00e7oise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:22Z","timestamp":1776846862000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457466","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}